BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Blogs » BioWorld MedTech Perspectives » Medtronic plans to enter ED market

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular

Medtronic plans to enter ED market

Nov. 4, 2011
By Omar Ford
No Comments

Medtronic has the potential to be a trend setter with its attempt to have drug eluting stents (DES) treat erectile dysfunction (ED).

The device maker recently moved one step closer in this effort as it reported that it had completed its ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), feasibility study.

The device, which hasn't been named yet, will be inserted into the pelvic area of the body. More specifically the stent is delivered using a catheter threaded up to the pelvis, where the pudendal artery is located. It was placed in the artery, opening the vessel and allowing for better blood flow.

In a large number of cases, ED is caused by vascular disease due to the deterioration of the endothelium. The company said that its DES is ideal because it preserves endothelial function of the native vessels.

The theory behind the stent treatment is that, ED could be thought of as a sort of penile angina and could in fact be treated much the same way the heart is treated by DES.

But not all ED stems from the same causes. Sometimes there are confidence and psychological issues associated with the condition. In order to totally corner this market Medtronic is going to have to do some hefty research and really drill down to determine what the patient population would be. That’s going to bethe company's greatest challenge.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing